British Journal of Cancer - Table of Contents alert Volume 119 Issue 9

Advertisement Nature Outlook: Brain cancer The uncontrolled growth of a tumour inside the brain creates an extraordinarily potent threat to our being. A diagnosis of brain cancer still carries the high likelihood of death within five years. But efforts to prolong survival are advancing on several fronts. Access free online Produced with support from Novocure TABLE OF CONTENTS Volume 119, Issue 9 In this issue Editorial Consensus Statement Article Brief Communication Article Correspondence Also new AOP Editorial Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) Min Yuen Teo & Howard I. Scher British Journal of Cancer 2018 119 :1041 - 1043; October 22, 2018; 10.1038/s41416-018-0239-y Abstract | Full Text Consensus Statement Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK Robert A. Watson, Hugo De La Peña, Maria T. Tsakok, Johnson Joseph, Sara Stoneham et al. British Journal of Cancer 2018 119 :1044 - 1051; October 25, 2018; 10.1038/s41416-018-0300-x Abstract | Full Text Article Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study) Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, Fernando López-Campos, Maria I. Saez et al. British Journal of Cancer 2018 119 :1052 - 1059; August 21, 2018; 10.1038/s41416-018-0123-9 Abstract | Full Text Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer Jai N. Patel, Ioana Braicu, Kirsten M. Timms, Cara Solimeno, Placede Tshiaba et al. British Journal of Cancer 2018 119 :1060 - 1066; October 15, 2018; 10.1038/s41416-018-0268-6 Abstract | Full Text Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy B. G. Wortman, C. L. Creutzberg, H. Putter, I. M. Jürgenliemk-Schulz, J. J. Jobsen et al. British Journal of Cancer 2018 119 :1067 - 1074; October 25, 2018; 10.1038/s41416-018-0310-8 Abstract | Full Text Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote et al. British Journal of Cancer 2018 119 :1075 - 1085; October 24, 2018; 10.1038/s41416-018-0271-y Abstract | Full Text Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study Pamela Munster, Ian E. Krop, Patricia LoRusso, Cynthia Ma, Barry A. Siegel et al. British Journal of Cancer 2018 119 :1086 - 1093; October 26, 2018; 10.1038/s41416-018-0235-2 Abstract | Full Text Statins attenuate outgrowth of breast cancer metastases Colin H. Beckwitt, Amanda M. Clark, Bo Ma, Diana Whaley, Zoltán N. Oltvai et al. British Journal of Cancer 2018 119 :1094 - 1105; November 07, 2018; 10.1038/s41416-018-0267-7 Abstract | Full Text Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells Souvik Chakraborty, Chang Jiang, David Gau, Michael Oddo, Zhijie Ding et al. British Journal of Cancer 2018 119 :1106 - 1117; October 15, 2018; 10.1038/s41416-018-0284-6 Abstract | Full Text Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma Nada M. S. Al-Saffar, Helen Troy, Anne-Christine Wong Te Fong, Roberta Paravati, L. Elizabeth Jackson et al. British Journal of Cancer 2018 119 :1118 - 1128; October 31, 2018; 10.1038/s41416-018-0242-3 Abstract | Full Text Brief Communication Breast osteoblast-like cells: a new biomarker for the management of breast cancer Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci & Elena Bonanno British Journal of Cancer 2018 119 :1129 - 1132; October 17, 2018; 10.1038/s41416-018-0255-y Abstract | Full Text Article Phenotype-independent DNA methylation changes in prostate cancer Davide Pellacani, Alastair P. Droop, Fiona M. Frame, Matthew S. Simms, Vincent M. Mann et al. British Journal of Cancer 2018 119 :1133 - 1143; October 15, 2018; 10.1038/s41416-018-0236-1 Abstract | Full Text Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment Torfinn S. Madssen, Inger Thune, Vidar G. Flote, Steinar Lundgren, Gro F. Bertheussen et al. British Journal of Cancer 2018 119 :1144 - 1154; November 07, 2018; 10.1038/s41416-018-0211-x Abstract | Full Text A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers Claudia J. C. Meurs, Joost van Rosmalen, Marian B. E. Menke-Pluijmers, Bert P. M. ter Braak, Linda de Munck et al. British Journal of Cancer 2018 119 :1155 - 1162; October 17, 2018; 10.1038/s41416-018-0276-6 Abstract | Full Text Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study Laila Sara Arroyo-Mühr, Camilla Lagheden, Emilie Hultin, Carina Eklund, Hans-Olov Adami et al. British Journal of Cancer 2018 119 :1163 - 1168; October 22, 2018; 10.1038/s41416-018-0311-7 Abstract | Full Text Correspondence Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study' Richard G. Stevens British Journal of Cancer 2018 119 :1169 - 1169; October 03, 2018; 10.1038/s41416-018-0058-1 Abstract | Full Text Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study" Louise E Johns, Michael E Jones, Minouk J Schoemaker, Emily McFadden, Alan Ashworth et al. British Journal of Cancer 2018 119 :1170 - 1170; October 17, 2018; 10.1038/s41416-018-0177-8 Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. This email has been sent to edgeblog.alerts.2011.001@gmail.com. If you no longer wish to receive the email alerts from British Journal of Cancer click here to unsubscribe . If you wish to discontinue all email services from Nature Research please click here to unsubscribe . For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.